What is Refocus Group?
Refocus Group, Inc., established in 1994 and based in Dallas, Texas, is dedicated to the research and development of innovative treatments for human vision disorders, with a primary focus on presbyopia. The company's lead investigational product is the VisAbility Micro-Insert System, currently undergoing clinical trials for binocular presbyopic treatment. Refocus Group serves both patients and eye care professionals, aiming to advance the standard of care in ophthalmic solutions.
How much funding has Refocus Group raised?
Refocus Group has raised a total of $15.3M across 2 funding rounds:
Unspecified
$15M
Debt
$350K
Unspecified (2016): $15M with participation from WP Global Partners and MedCare Investment Funds
Debt (2020): $350K led by PPP
Key Investors in Refocus Group
MedCare Investment Funds
MedCare Investment Funds manages approximately $1 billion in assets, with a strong focus on the medical and healthcare services industry. They have the flexibility to invest in companies at any stage of development, aiming for capital appreciation and long-term business growth.
WP Global Partners
WP Global Partners backs enterprises essential to U.S. employment and economic growth, utilizing a hybrid investment strategy. They focus on small and medium businesses, aiming to generate risk-adjusted returns and provide strategic guidance.
What's next for Refocus Group?
With a significant enterprise-level funding context and a recent major strategic investment, Refocus Group is positioned for accelerated development and potential commercialization of its VisAbility Micro-Insert System. The company's trajectory suggests a focus on navigating clinical trials and preparing for market entry, leveraging its accumulated capital to advance its mission in treating vision disorders. Future growth will likely involve scaling operations and expanding its reach within the medical device sector.
See full Refocus Group company page
